PHAT
Phathom Pharmaceuticals, Inc. [PHAT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PHAT Stock Summary
Top 10 Correlated ETFs
PHAT
Top 10 Correlated Stocks
PHAT
In the News
PHAT Financial details
Company Rating
Neutral
Market Cap
592.96M
Income
-201.45M
Revenue
682K
Book val./share
-1.27
Cash/share
6.66
Dividend
-
Dividend %
-
Employees
452
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-2.55
Forward P/E
-
PEG
0.8
P/S
-
P/B
-26.61
P/C
1.35
P/FCF
-3.51
Quick Ratio
8.91
Current Ratio
9.46
Debt / Equity
-1.91
LT Debt / Equity
-1.9
-
-
EPS (TTM)
-3.88
EPS next Y
-
EPS next Q
-
EPS this Y
-31.05%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
82.89%
-
-
-
-
SMA20
11.11%
SMA50
42.86%
SMA100
42.86%
Inst Own
80.42%
Inst Trans
0.8%
ROA
-78%
ROE
449%
ROC
-0.68%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.065-17.019
52W High
-47%
52W Low
+50.17%
RSI
42
Rel Volume
0.35
Avg Volume
917.88K
Volume
319.15K
Perf Week
-13.94%
Perf Month
1.46%
Perf Quarter
4.04%
Perf Half Y
-1.74%
-
-
-
-
Beta
0.627
-
-
Volatility
0.38%, 1.14%
Prev Close
-4.96%
Price
9.01
Change
-6.92%
PHAT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0.01 | |
| Net income per share | -8.48 | -4.01 | -4 | -5.7 | -3.93 | |
| Operating cash flow per share | -1.48 | -2.1 | -4.02 | -3.75 | -2.68 | |
| Free cash flow per share | -2.5 | -2.13 | -4.03 | -3.77 | -2.71 | |
| Cash per share | 9.86 | 8.65 | 4.95 | 3.97 | 7.44 | |
| Book value per share | 9.22 | 5.85 | 1.95 | -1.91 | -1.42 | |
| Tangible book value per share | 9.22 | 5.85 | 1.95 | -1.91 | -1.42 | |
| Share holders equity per share | 9.22 | 5.85 | 1.95 | -1.91 | -1.42 | |
| Interest debt per share | 1.12 | 1.61 | 2.65 | 3.18 | 3.53 | |
| Market cap | 770.04M | 1.1B | 727.85M | 438.91M | 468.27M | |
| Enterprise value | 549.85M | 865.36M | 635.93M | 380.59M | 225.91M | |
| P/E ratio | -3.67 | -8.28 | -4.91 | -1.97 | -2.32 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 686.61 | |
| POCF ratio | -21.09 | -15.84 | -4.9 | -3 | -3.4 | |
| PFCF ratio | -12.47 | -15.61 | -4.89 | -2.97 | -3.36 | |
| P/B Ratio | 3.38 | 5.68 | 10.09 | -5.87 | -6.44 | |
| PTB ratio | 3.38 | 5.68 | 10.09 | -5.87 | -6.44 | |
| EV to sales | 0 | 0 | 0 | 0 | 331.24 | |
| Enterprise value over EBITDA | -3.55 | -6.95 | -4.64 | -2.23 | -1.42 | |
| EV to operating cash flow | -15.06 | -12.42 | -4.28 | -2.6 | -1.64 | |
| EV to free cash flow | -8.9 | -12.24 | -4.27 | -2.58 | -1.62 | |
| Earnings yield | -0.27 | -0.12 | -0.2 | -0.51 | -0.43 | |
| Free cash flow yield | -0.08 | -0.06 | -0.2 | -0.34 | -0.3 | |
| Debt to equity | 0.1 | 0.25 | 1.27 | -1.3 | -1.91 | |
| Debt to assets | 0.09 | 0.17 | 0.48 | 0.59 | 0.34 | |
| Net debt to EBITDA | 1.42 | 1.91 | 0.67 | 0.34 | 1.52 | |
| Current ratio | 68.2 | 5.25 | 9.86 | 6.12 | 10.25 | |
| Interest coverage | -25.43 | -27.43 | -19.9 | -6.32 | -3.99 | |
| Income quality | 0.14 | 0.54 | 1.03 | 0.74 | 0.68 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 73.17 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.69 | 0.01 | 0 | 0.01 | 0.01 | |
| Capex to revenue | 0 | 0 | 0 | 0 | -2.4 | |
| Capex to depreciation | -3.16K | -3.22 | -0.63 | -1.68 | -2.84 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 66.02 | |
| Graham number | 41.94 | 22.97 | 13.25 | 15.66 | 11.2 | |
| ROIC | -0.35 | -0.53 | -0.84 | -8.08 | -2.99 | |
| Return on tangible assets | -0.82 | -0.45 | -0.78 | -1.35 | -0.49 | |
| Graham Net | 8.68 | 5.62 | 1.78 | -2.15 | -2.02 | |
| Working capital | 251.85M | 235.84M | 167.61M | 134.28M | 358.65M | |
| Tangible asset value | 227.96M | 194.27M | 72.16M | -74.81M | -72.76M | |
| Net current asset value | 226.38M | 190.53M | 69.25M | -79.11M | -89.17M | |
| Invested capital | 0.1 | 0.25 | 1.27 | -1.3 | -1.91 | |
| Average receivables | 0 | 41K | 41K | 0 | 818.5K | |
| Average payables | 377K | 8.74M | 10.97M | 7.57M | 11.3M | |
| Average inventory | 0 | -41K | -41K | 0 | 604K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 876.11 | |
| Days payables outstanding | 31.89K | 20.42K | 3.61K | 5.89K | 27.54K | |
| Days of inventory on hand | 0 | -99.77 | 0 | 0 | 2.64K | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0.42 | |
| Payables turnover | 0.01 | 0.02 | 0.1 | 0.06 | 0.01 | |
| Inventory turnover | 0 | -3.66 | 0 | 0 | 0.14 | |
| ROE | -0.92 | -0.69 | -2.05 | 2.98 | 2.77 | |
| Capex per share | -1.02 | -0.03 | -0.01 | -0.03 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0.01 | |
| Net income per share | -1.54 | -0.89 | -0.84 | -0.76 | -1.39 | |
| Operating cash flow per share | -0.99 | -0.94 | -0.46 | -0.56 | -0.76 | |
| Free cash flow per share | -1 | -0.94 | -0.46 | -0.58 | -0.77 | |
| Cash per share | 3.76 | 3.06 | 5.13 | 3.76 | 6.66 | |
| Book value per share | -1.81 | -2.13 | 0.36 | -0.31 | -1.27 | |
| Tangible book value per share | -1.81 | -2.13 | 0.36 | -0.31 | -1.27 | |
| Share holders equity per share | -1.81 | -2.13 | 0.36 | -0.31 | -1.27 | |
| Interest debt per share | 2.58 | 2.54 | 2.25 | 1.59 | 2.65 | |
| Market cap | 463.51M | 302.41M | 694.53M | 588.83M | 523.1M | |
| Enterprise value | 405.19M | 271.13M | 544.99M | 475.76M | 280.73M | |
| P/E ratio | -1.83 | -2.01 | -4.24 | -3.4 | -1.64 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 767.01 | |
| POCF ratio | -11.39 | -7.62 | -31.29 | -18.45 | -11.94 | |
| PFCF ratio | -11.28 | -7.58 | -31.28 | -17.92 | -11.82 | |
| P/B Ratio | -6.2 | -3.35 | 39.46 | -33.13 | -7.19 | |
| PTB ratio | -6.2 | -3.35 | 39.46 | -33.13 | -7.19 | |
| EV to sales | 0 | 0 | 0 | 0 | 411.63 | |
| Enterprise value over EBITDA | -8.92 | -9.48 | -17.45 | -13.34 | -4.23 | |
| EV to operating cash flow | -9.96 | -6.83 | -24.55 | -14.91 | -6.41 | |
| EV to free cash flow | -9.86 | -6.8 | -24.54 | -14.48 | -6.34 | |
| Earnings yield | -0.14 | -0.12 | -0.06 | -0.07 | -0.15 | |
| Free cash flow yield | -0.09 | -0.13 | -0.03 | -0.06 | -0.08 | |
| Debt to equity | -1.3 | -1.09 | 5.64 | -5.66 | -1.91 | |
| Debt to assets | 0.59 | 0.68 | 0.37 | 0.42 | 0.34 | |
| Net debt to EBITDA | 1.28 | 1.09 | 4.79 | 3.17 | 3.65 | |
| Current ratio | 6.12 | 9.68 | 11.96 | 9.46 | 10.25 | |
| Interest coverage | -4.86 | -3.26 | -3.3 | 3.53 | -5.36 | |
| Income quality | 0.74 | 1.05 | 0.54 | 0.74 | 0.55 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 89.34 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 19.64 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.01 | 0 | 0.03 | 0.01 | |
| Capex to revenue | 0 | 0 | 0 | 0 | -0.7 | |
| Capex to depreciation | -2.45 | -1.47 | -0.05 | -7.76 | -2.57 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 36.05 | |
| Graham number | 7.91 | 6.53 | 2.63 | 2.32 | 6.3 | |
| ROIC | -2.23 | -3.07 | -0.33 | -0.49 | -0.82 | |
| Return on tangible assets | -0.39 | -0.26 | -0.15 | -0.18 | -0.19 | |
| Graham Net | -2.04 | -2.47 | 0.03 | -0.72 | -1.8 | |
| Working capital | 134.28M | 125.4M | 236.17M | 202.75M | 358.65M | |
| Tangible asset value | -74.81M | -90.2M | 17.6M | -17.77M | -72.76M | |
| Net current asset value | -79.11M | -94.36M | 10.28M | -28.04M | -89.17M | |
| Invested capital | -1.3 | -1.09 | 5.64 | -5.66 | -1.91 | |
| Average receivables | 0 | 0 | 0 | 0 | 818.5K | |
| Average payables | 8.53M | 7.36M | 4.44M | 4.96M | 9.18M | |
| Average inventory | 0 | 0 | 55.5K | 111K | 659.5K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 216.03 | |
| Days payables outstanding | 5.36K | 2.91K | 3.03K | 4.29K | -5.09K | |
| Days of inventory on hand | 0 | 0 | 81.22 | 82.56 | -487.53 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0.42 | |
| Payables turnover | 0.02 | 0.03 | 0.03 | 0.02 | -0.02 | |
| Inventory turnover | 0 | 0 | 1.11 | 1.09 | -0.18 | |
| ROE | 0.85 | 0.42 | -2.33 | 2.43 | 1.09 | |
| Capex per share | -0.01 | -0.01 | 0 | -0.02 | -0.01 |
PHAT Frequently Asked Questions
What is Phathom Pharmaceuticals, Inc. stock symbol ?
Phathom Pharmaceuticals, Inc. is a US stock , located in Florham park of Nj and trading under the symbol PHAT
What is Phathom Pharmaceuticals, Inc. stock quote today ?
Phathom Pharmaceuticals, Inc. stock price is $9.01 today.
Is Phathom Pharmaceuticals, Inc. stock public?
Yes, Phathom Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 917.88K
- Market Capitalization 592.96M
- Employee 452
- CEO Ms. Terrie J. Curran
- Headquarters Florham Park,NJ,US
- IPO Date 2019-10-25
-
Website
https://www.phathompharma.com 
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
